Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1995-8-18
pubmed:abstractText
We have previously shown that administration of cyclosporine A (CsA) plus interferon-gamma (IFN) after chemotherapy to mice bearing B16 melanoma results in the generation of cells with major histocompatibility complex (MHC)-unrestricted cytotoxicity in vitro and in vivo; the antitumor effect of these cells could be attenuated by normal spleen cells. This study shows that antitumor effect after treatment with CsA plus IFN after chemotherapy was mediated by T and natural killer (NK) cells, both in vitro and in vivo. Infusion of purified T or NK cells into secondary recipients after chemotherapy resulted in a significant control in the dissemination of tumor as compared to chemotherapy alone. The antitumor potential of NK cells was at least 10 times greater than that of T cells. The effector cells could inhibit the proliferation of tumor cells in vitro without a contact between the effector and tumor cells, suggesting that antitumor effect in this system was partly related to the secretion of cytotoxic factors by the effector cells. Infusion of normal spleen cells inhibited the antitumor effect of adoptively transferred effector cells. This study defines the nature of effector cells involved in mediating the antitumor effect in this model; the optimal efficacy of these cells in the recipient is possibly related to the abolition of a suppressor system by chemotherapy.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1067-5582
pubmed:author
pubmed:issnType
Print
pubmed:volume
17
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
131-40
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed:year
1995
pubmed:articleTitle
Induction of antitumor effect by treatment with cyclosporine A plus interferon-gamma after chemotherapy: role of cytotoxic cells.
pubmed:affiliation
Bone Marrow Transplantation Program, Georgetown University, Washington, DC, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.